| A Study of BMS-986207 Given Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Advanced Solid Tumors (NCT02913313) | Bristol-Myers Squibb | 2016-11-30 |
| Generation of Positive Biological Samples to Epoetin for Doping Control. (NCT02920372) | Parc de Salut Mar | 2016-11-30 |
| Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumors (NCT02744287) | Regeneron Pharmaceuticals | 2016-11-30 |
| A Pharmacokinetic Study of Modified Release (MR) Formulations of MIN-101 in Healthy Subjects (NCT03038646) | Minerva Neurosciences | 2016-11-30 |
| Study of BMS-986012 in Subjects With Small Cell Lung Caner (NCT02949895) | Bristol-Myers Squibb | 2016-11-29 |
| A Study Conducted in Healthy Male Subjects to Investigate the Safety and Tolerability of AC-76, Its Fate in the Body, and Its Effect on the Body (NCT03173625) | Viatris Innovation GmbH | 2016-11-29 |
| Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine (NCT02996773) | University of Arizona | 2016-11-29 |
| A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous (SC) Administered Alirocumab in Healthy Chinese Subjects (NCT02979015) | Sanofi | 2016-11-29 |
| Safety and Efficacy Study of NFC-1 in Subjects Aged 12-17 Years With 22q11.2DS & Associated Neuropsychiatric Conditions (NCT02895906) | Aevi Genomic Medicine, LLC, a Cerecor company | 2016-11-28 |
| Drug-Drug Interaction Study Between DWC20155 / DWC20156 and DWC20162 in Healthy Volunteers (NCT02952755) | Daewoong Pharmaceutical Co. LTD. | 2016-11-28 |
| A Study Of PF-06747143, As Single Agent Or In Combination With Standard Chemotherapy In Adult Patients With Acute Myeloid Leukemia (NCT02954653) | Pfizer | 2016-11-28 |
| Cisplatin, Intensity-Modulated Radiation Therapy, and Pembrolizumab in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma (NCT02775812) | National Cancer Institute (NCI) | 2016-11-28 |
| Study of a Humanized Antibody Initiated 2 Months After an HLA Matched Allogenic Stem Cell Transplantation (NCT02921685) | Institut Paoli-Calmettes | 2016-11-28 |
| MITIGATE-NeoBOM: A Study to Evaluate 68Ga- NeoBOMB1 in Patients With Advanced TKI-treated GIST Using PET/CT (NCT02931929) | Medical University Innsbruck | 2016-11-28 |
| Safety and Protective Efficacy of IV Immunization With Cryopreserved PfSPZ Under A/P Chemoprophylaxis (NCT02858817) | University Hospital Tuebingen | 2016-11-28 |
| Trial of BMS-986012 in Combination With Platinum and Etoposide (NCT02815592) | Bristol-Myers Squibb | 2016-11-28 |
| Phase I/II Study of U3-1402 in Subjects With Human Epidermal Growth Factor Receptor 3 (HER3) Positive Metastatic Breast Cancer (NCT02980341) | Daiichi Sankyo Co., Ltd. | 2016-11-28 |
| Pregabalin add-on for Neuropathic Pain in Cervical Myelopathy (NCT03618589) | Seoul National University Hospital | 2016-11-26 |
| 18F-AV-1451 High Resolution Autopsy Study (NCT02350634) | Avid Radiopharmaceuticals | 2016-11-26 |
| A Study to Assess Safety, Tolerability and Pharmacokinetics of GLPG2737 in Healthy Subjects (NCT03410979) | Lakefront Biotherapeutics NV | 2016-11-25 |
| A Study to Assess the Effect of Particle Size of AZD7594 on Pharmacokinetics (PK) After a Single Inhaled Dose When Administered Using the Dry Powder Inhaler in Healthy Volunteers (NCT02928354) | AstraZeneca | 2016-11-25 |
| Pharmaco-Scintigraphic Study to Evaluate the Release Profile of Metronidazole Benzoate Capsules (NCT02911298) | Tillotts Pharma AG | 2016-11-25 |
| A Study to Evaluate the Disposition of Drug in Body and Safety After Administration of Single Inhaled Doses of Drugs Abediterol and AZD7594 Administered Alone, in Fixed Dose Combination and in Free Combination Using the Dry Powder Inhaler in Healthy Male Participants (NCT02967159) | AstraZeneca | 2016-11-24 |
| A Study of Anti-Lewis Y Chimeric Antigen Receptor-T Cells (LeY-CAR-T) in Patients With Solid Tumours (NCT03851146) | Peter MacCallum Cancer Centre, Australia | 2016-11-24 |
| Study to Identify the Optimal Adjuvant Combination Scheme of Ipilimumab and Nivolumab in Melanoma Patients (NCT02437279) | The Netherlands Cancer Institute | 2016-11-24 |
| Comparison of Inhaled Oxytocin (IH) With Intramuscular (IM) Oxytocin in Pregnant Women and With Intravenous (IV) Oxytocin in Healthy Non-pregnant Women (NCT02999100) | GlaxoSmithKline | 2016-11-23 |
| Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors (NCT02988817) | Genmab | 2016-11-23 |
| Pharmacokinetics and Safety of Ceftobiprole in Neonates and Infants up to 3 Months Treated With Systemic Antibiotics (NCT02527681) | Basilea Pharmaceutica | 2016-11-22 |
| Phase 1 Absorption Distribution Metabolism and Excretion of AQX-1125 (NCT03185195) | Aquinox Pharmaceuticals (Canada) Inc. | 2016-11-22 |
| Study to Investigate the Food Effect and Oral Bioavailability of Tablet Formulations Relative to Suspension Formulation of JNJ-54416076 in Healthy Participants (NCT02951845) | Janssen Research & Development, LLC | 2016-11-22 |
| A Study to Evaluate the Effects of ABX-1431 on Patients With Functional Dyspepsia (NCT02875678) | Abide Therapeutics | 2016-11-22 |
| Trial of Magrolimab (Hu5F9-G4) in Combination With Rituximab or Rituximab + Chemotherapy in Participants With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma (NCT02953509) | Gilead Sciences | 2016-11-21 |
| Pharmacokinetics of Lanraplenib in Adults With Impaired Renal Function (NCT02959138) | Gilead Sciences | 2016-11-21 |
| TAK-071 Scopolamine-Induced Cognitive Impairment Study (NCT02918266) | Takeda | 2016-11-21 |
| Study of Antibody Drug Conjugate in Patients With Advanced Breast Cancer Expressing HER2 (NCT02952729) | Mersana Therapeutics | 2016-11-21 |
| Pharmacokinetics of Efavirenz in the Presence of Rifampicin and Isoniazid (NCT02832778) | St Stephens Aids Trust | 2016-11-21 |
| A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CC-90006 in Healthy Subjects (NCT02934269) | Celgene | 2016-11-21 |
| Ixazomib (MLN9708) in Combination With Carboplatin in Pretreated Women With Advanced Triple Negative Breast Cancer (NCT02993094) | Arbeitsgemeinschaft medikamentoese Tumortherapie | 2016-11-21 |
| Lung Deposition of Beclometasone Dipropionate/Formoterol Fumarate/Glycopyrronium Bromide Administered Via pMDI in Healthy, Asthmatic and COPD Patients (NCT02975843) | Chiesi Farmaceutici S.p.A. | 2016-11-21 |
| Serum Pharmacokinetic Disposition and Urinary Excretion of Albendazole (NCT03192449) | Universidad Nacional de Salta | 2016-11-21 |
| Crossover Study to Evaluate the Effect of Lemborexant Versus Placebo and Zolpidem on Postural Stability, Auditory Awakening Threshold, and Cognitive Performance in Healthy Subjects 55 Years and Older (NCT03008447) | Eisai Inc. | 2016-11-21 |
| A Pilot Study of Vitamin D in Boys With X-linked Adrenoleukodystrophy (NCT02595489) | Stanford University | 2016-11-21 |
| A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers (NCT02908906) | Janssen Research & Development, LLC | 2016-11-21 |
| Study of the Safety, Tolerability and Pharmacokinetics of TMB-607 in HIV-Negative Volunteers (NCT03110549) | TaiMed Biologics Inc. | 2016-11-21 |
| A Trial to Find and Investigate a Safe Dose of a New Substance (BI 754091) for Patients With Solid Tumours (NCT02952248) | Boehringer Ingelheim | 2016-11-21 |
| A Study of LY3200882 in Participants With Solid Tumors (NCT02937272) | Eli Lilly and Company | 2016-11-21 |
| The Influence of Oxytocin on Socio-communicative Sensitivity (NCT03096249) | KU Leuven | 2016-11-21 |
| Ipilimumab for Head and Neck Cancer Patients (NCT02812524) | Providence Health & Services | 2016-11-18 |
| H3.3K27M Peptide Vaccine With Nivolumab for Children With Newly Diagnosed DIPG and Other Gliomas (NCT02960230) | Sabine Mueller, MD, PhD | 2016-11-18 |
| A Study of ABBV-428, an Immunotherapy, in Subjects With Advanced Solid Tumors (NCT02955251) | AbbVie | 2016-11-18 |
| Study of Artemether-lumefantrine, Amodiaquine and Primaquine in Healthy Subjects (NCT02696954) | University of Oxford | 2016-11-18 |
| Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365) (NCT02861573) | Merck Sharp & Dohme LLC | 2016-11-17 |
| Study of Finerenone to Investigate a Paediatric Formulation in Healthy Male Subjects (NCT02957396) | Bayer | 2016-11-17 |
| Study of Samalizumab in Patients With Advanced Cancer (NCT02987504) | Alexion Pharmaceuticals, Inc. | 2016-11-17 |
| Generation of Positive Biological Samples to Leuprolide Acetate for Doping Control (NCT02920359) | Parc de Salut Mar | 2016-11-17 |
| A Phase I/II Clinical Trial on the Per-operative Intratumoral Administration of Myeloid Dendritic Cells Plus Ipilimumab and Nivolumab, Followed by Repeated Intracavitary Plus Intravenous Administration of Nivolumab in Patients With Recurrent Glioblastoma. (NCT03233152) | Universitair Ziekenhuis Brussel | 2016-11-17 |
| Decitabine With GCLAM for Adults With Newly Diagnosed, Relapsed, or Refractory AML or High-Risk MDS (NCT02921061) | Fred Hutchinson Cancer Center | 2016-11-17 |
| A Dose Escalation Trial of SBRT After Induction Chemotherapy for Locally Advanced Pancreatic Cancer (NCT02873598) | University of Colorado, Denver | 2016-11-17 |
| Study of Finerenone to Investigate a Paediatric Formulation in Healthy Male Volunteers (NCT02956109) | Bayer | 2016-11-16 |
| Durvalumab And Radiation Therapy Followed by Adjuvant Durvalumab in Patients With Urothelial Cancer (T2-4 N0-2 M0) of the Bladder (NCT02891161) | Monika Joshi, MD | 2016-11-16 |
| Pharmacokinetic (PK) Bioequivalence and Pharmacodynamics (PD) of Julphar Insulin N and Huminsulin® Basal (NCT02634528) | Julphar Gulf Pharmaceutical Industries | 2016-11-16 |
| Pharmacokinetics Study of MCI-186 in Subjects With Mild or Moderate Hepatic Impairment (NCT03289234) | Shionogi | 2016-11-16 |
| Phase 1 Dose Escalation and PK Study of Cu(II)ATSM in ALS/MND (NCT02870634) | Collaborative Medicinal Development Pty Limited | 2016-11-16 |
| Test Re-Test Reliability of [11C]PF-06809247 as a Novel PET Tacer (NCT03100136) | Pfizer | 2016-11-16 |
| Study of PF614 Compared to OxyContin® in Healthy Volunteers (PF614-101) (NCT02454712) | Ensysce Biosciences | 2016-11-16 |
| Autologous Muscle Derived Cells for Underactive Bladder (NCT02463448) | Jason Gilleran | 2016-11-16 |
| JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NCT02706405) | Fred Hutchinson Cancer Center | 2016-11-15 |
| Ascending Dose Study of Genome Editing by Zinc Finger Nuclease Therapeutic SB-FIX in Subjects With Severe Hemophilia B (NCT02695160) | Sangamo Therapeutics | 2016-11-15 |
| The Prevention of Hypotension After Epidural Analgesia After Major Surgery (NCT02722746) | University of Florida | 2016-11-15 |
| Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma (NCT02568553) | National Cancer Institute (NCI) | 2016-11-15 |
| Ibrutinib and Nivolumab in Treating Patients With Previously-Treated Metastatic Kidney Cancer (NCT02899078) | University of California, Davis | 2016-11-15 |
| A Study to Investigate the Absorption, Metabolism and Excretion of [14C]ASP8273 in Subjects With Solid Tumors (NCT02674555) | Astellas Pharma Global Development, Inc. | 2016-11-15 |
| A Phase 1 Study of INCMGA00012 in Patients With Advanced Solid Tumors (NCT03059823) | Incyte Corporation | 2016-11-15 |
| A Trial Investigating the Safety, Tolerability, Pharmacokinetics (the Exposure of the Trial Drug in the Body) and Pharmacodynamics (the Effect of the Investigated Drug on the Body) of Insulin 287 in Subjects With Type 2 Diabetes (NCT02964104) | Novo Nordisk A/S | 2016-11-15 |
| Study to Assess Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Healthy Volunteers and Participants With Paroxysmal Nocturnal Hemoglobinuria (NCT03157635) | Hoffmann-La Roche | 2016-11-14 |
| Pharmacokinetic/Pharmacodynamic Drug-drug Interaction of Evogliptin 5mg and Glimepiride 4mg (NCT02954822) | Dong-A ST Co., Ltd. | 2016-11-14 |
| Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCT02713386) | NRG Oncology | 2016-11-14 |
| A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer (NCT02779751) | Eli Lilly and Company | 2016-11-14 |
| A Phase I/II Clinical Study of SAF-189s in Non-small Cell Lung Cancer (NSCLC) Patients (NCT04237805) | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | 2016-11-14 |
| A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes (NCT02848001) | Celgene | 2016-11-14 |
| The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UTTR1147A in Participants With Neuropathic Non-Healing Diabetic Foot Ulcers (NCT02833389) | Genentech, Inc. | 2016-11-14 |
| A Study to Assess Safety, Tolerability and Pharmacokinetics of GLPG2451 in Healthy Male Subjects (NCT03214614) | Lakefront Biotherapeutics NV | 2016-11-14 |
| A Study Comparing Two Formulations of Insulin Glargine in Healthy Participants (NCT02955953) | Eli Lilly and Company | 2016-11-14 |
| A Study to Evaluate Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of JNJ-64179375 in Healthy Male Subjects (NCT02949206) | Janssen Research & Development, LLC | 2016-11-14 |
| Trial of Stereotactic Body Radiotherapy With Concurrent Pembrolizumab in Metastatic Urothelial Cancer (NCT02826564) | University Hospital, Ghent | 2016-11-14 |
| Ruxolitinib Phosphate and Chemotherapy Given Before and After Reduced Intensity Donor Stem Cell Transplant in Treating Patients With Myelofibrosis (NCT02917096) | City of Hope Medical Center | 2016-11-13 |
| Safety and Tolerability of PF-06818883 in Healthy Subjects (NCT03020784) | Pfizer | 2016-11-11 |
| A Study of Investigational Drug CFI-402257 in Patients With Advanced Solid Tumors (NCT02792465) | University Health Network, Toronto | 2016-11-11 |
| Effects of Altered Formulation on the Bioequivalence of Tacrolimus in Healthy Female and Male Volunteeers (NCT02341274) | Indiana University | 2016-11-11 |
| A Pharmacokinetic Interaction Study Between Odalasvir, Given as a Single Agent or in Combination With Simeprevir, and Dabigatran Etexilate Mesylate in Healthy Participants (NCT02945020) | Janssen Research & Development, LLC | 2016-11-10 |
| A Study to Evaluate Escalating Doses of ASP1235 (AGS62P1) Given as Monotherapy in Subjects With Acute Myeloid Leukemia (AML) (NCT02864290) | Astellas Pharma Global Development, Inc. | 2016-11-10 |
| Trial Of Pembrolizumab And Nintedanib (NCT02856425) | Gustave Roussy, Cancer Campus, Grand Paris | 2016-11-10 |
| Drug Interaction Study of CT1812 in Healthy Volunteers (NCT03716427) | Cognition Therapeutics | 2016-11-10 |
| Suprachoroidal Injection of CLS-TA Alone or With Aflibercept in Subjects With Diabetic Macular Edema (NCT02949024) | Clearside Biomedical, Inc. | 2016-11-10 |
| Drug-drug Interaction Study Between Orally Administered Rifampicin and Vilaprisan (NCT02975440) | Bayer | 2016-11-10 |
| A Study to Evaluate the Effect of Severe Renal Impairment on the Single-dose Pharmacokinetics of Odalasvir (NCT02961660) | Janssen Research & Development, LLC | 2016-11-09 |
| A Study Evaluating Safety and Efficacy of Obinutuzumab, Polatuzumab Vedotin (Pola), and Atezolizumab (Atezo) in Participants With Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab, Atezo, and Pola in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (NCT02729896) | Hoffmann-La Roche | 2016-11-09 |
| A Study to Evaluate the Safety, Tolerability and Immunogenicity of Two Vaccinations of Ad26.RSV.preF One Year Apart in Adults Aged 60 Years and Older in Stable Health (NCT02926430) | Janssen Vaccines & Prevention B.V. | 2016-11-08 |
| A Study of LY3041658 in Participants With Skin Diseases (NCT02896868) | Eli Lilly and Company | 2016-11-08 |
| A Study to Assess the Relative Oral Bioavailability of a Single Dose of JNJ-53718678 Administered as Oral Concept Formulation Compared to the Current Oral Solution and to Assess the Effect of Food on the Pharmacokinetics of Oral Concept Formulation (NCT02945007) | Janssen Research & Development, LLC | 2016-11-08 |